TOP TEN perturbations for 1552818_a_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1552818_a_at
Selected probe(set): 207369_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1552818_a_at (207369_at) across 6673 perturbations tested by GENEVESTIGATOR:
systemic lupus erythematosus study 13 (untreated) / normal PBMC sample
Relative Expression (log2-ratio):-2.9216099Number of Samples:4 / 5
| Experimental | systemic lupus erythematosus study 13 (untreated) |
| Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists. | |
| Control | normal PBMC sample |
| Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. |
pancreatic islet study 3 (re-differentiated; NIH) / normal pancreatic islet sample
Relative Expression (log2-ratio):-2.3058977Number of Samples:4 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; NIH) |
| Pancreatic islet cells were expanded for 10 weeks and re-differentiated for 1 week according to National Institutes of Health (NIH) protocol. Re-differentiation phase: Expanded cells were cultured for 1 week in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml). | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pioglitazone study 4 (1uM; 6h) / normal PBMC sample
Relative Expression (log2-ratio):-2.1588535Number of Samples:5 / 5
| Experimental | pioglitazone study 4 (1uM; 6h) |
| Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects and cultured with pioglitazone. Freshly isolated PBMCs were cultured in RPMI/10% FBS in the presence of 1uM pioglitazone for 6 hours. ATC code: | |
| Control | normal PBMC sample |
| Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. |
systemic lupus erythematosus study 3 / normal blood sample
Relative Expression (log2-ratio):1.7496338Number of Samples:89 / 30
| Experimental | systemic lupus erythematosus study 3 |
| Blood samples derived from patients with anti-ribonuclear protein-positive (anti-RNP+) systemic lupus erythematosus (SLE). | |
| Control | normal blood sample |
| Blood samples from healthy individuals. |
influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.5890989Number of Samples:3 / 3
| Experimental | influenza virus study 10 (A/H5N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.4708338Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.4064932Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/H9N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.3328924Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/H5N2) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.3204012Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/pH1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
Ole e 1 dodecapeptide study 1 (allergic; pollen season) / Ole e 1 dodecapeptide study 1 (non-allergic; pollen season)
Relative Expression (log2-ratio):1.1237211Number of Samples:3 / 2
| Experimental | Ole e 1 dodecapeptide study 1 (allergic; pollen season) |
| Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from pollen-allergic patients were cultured for 24 hours in the presence of synthesized Ole e 1 dodecapeptides p2 + p3 (5µg/ml). The peptides: p2 (aa11-22) and p3 (aa22-33) are mainly recognized by non-allergic subjects and inducers of IL-10. The patients fulfilled the following criteria: seasonal rhinitis and/or asthma, a positive skin prick test for O. europaea pollen extract, and no previous immunotherapy. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias). | |
| Control | Ole e 1 dodecapeptide study 1 (non-allergic; pollen season) |
| Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from patients with no history of respiratory allergies were cultured for 24 hours in the presence of synthesized Ole e 1 dodecapeptides p2 + p3 (5µg/ml). The peptides: p2 (aa11-22) and p3 (aa22-33) are mainly recognized by non-allergic subjects and inducers of IL-10. All subjects underwent skin prick test for olive pollen allergy with whole O. europaea extract and a battery of common allergens. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias). |